Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells
Authors:
- 1 April 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (7) , 3723-3734
Abstract
Mediators of PI3K/AKT signaling have been implicated in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Studies have shown that inhibitors of PI3K/AKT signaling, such as wortmannin and LY294002, are able to inhibit CML and AML cell proliferation and synergize with targeted tyrosine kinase inhi-bitors. We investigated the ability of BAG956, a dual PI3K/PDK-1 inhibitor, to be used in combination with inhibitors of BCR-ABL and mutant FLT3, as well as with the mTOR inhibitor, rapamycin, and the rapamycin derivative, RAD001. BAG956 was shown to block AKT phosphorylation induced by BCR-ABL–, and induce apoptosis of BCR-ABL–expressing cell lines and patient bone marrow cells at concentrations that also inhibit PI3K signaling. Enhancement of the inhibitory effects of the tyrosine kinase inhibitors, imatinib and nilotinib, by BAG956 was demonstrated against BCR-ABL expressing cells both in vitro and in vivo. We have also shown that BAG956 is effective against mutant FLT3-expressing cell lines and AML patient bone marrow cells. Enhancement of the inhibitory effects of the tyrosine kinase inhibitor, PKC412, by BAG956 was demonstrated against mutant FLT3-expressing cells. Finally, BAG956 and rapamycin/RAD001 were shown to combine in a nonantagonistic fashion against BCR-ABL– and mutant FLT3-expressing cells both in vitro and in vivo.Keywords
This publication has 67 references indexed in Scilit:
- Evaluation of antileukaemic effects of rapamycin in patients with imatinib‐resistant chronic myeloid leukaemiaEuropean Journal of Clinical Investigation, 2007
- Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugsBlood, 2007
- Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemiasBlood, 2006
- Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDBlood, 2006
- PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathwaysLeukemia, 2005
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Blood, 2005
- Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometryBritish Journal of Haematology, 2004
- FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3Biochemical and Biophysical Research Communications, 2004
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- BCR/ABL Regulation of PI-3 Kinase ActivityLeukemia & Lymphoma, 1996